Sphingosine 1-phosphate (S1P), a multifunctional lipid mediator, regulates lymphocyte trafficking, vascular permeability and angiogenesis by activation of the S1P 1 receptor. This receptor is activated by FTY720-P, a phosphorylated derivative of the immunosuppressant and vasoactive compound FTY720. However, in contrast to the natural ligand S1P, FTY720-P appears to act as a functional antagonist, even though the mechanisms involved are poorly understood. In this study, we investigated the fate of endogenously-expressed S1P 1 receptor in agonistactivated human umbilical vein endothelial cells (HUVEC) and human embryonic kidney (HEK)293 cells expressing green fluorescent protein-tagged S1P 1 (S1P 1 -GFP). We show that FTY720-P is more potent than S1P at inducing receptor degradation. Pre-treatment with an antagonist of S1P 1 , VPC 44116, prevented receptor internalization and degradation. FTY720-P did not induce degradation of internalization-deficient S1P 1 receptor mutants. Further, siRNA-mediated down regulation of G protein-coupled receptor kinase-2 (GRK-2) and β-arrestin abolished FTY720-P-induced S1P 1 receptor degradation. These data suggest that agonist-induced phosphorylation of S1P 1 and subsequent endocytosis are required for FTY720-P-induced degradation of the receptor. S1P 1 degradation is blocked by MG132, a proteosomal inhibitor. Indeed, FTY720-P strongly induced polyubiquitinylation of S1P 1 receptor whereas S1P at concentrations that induced complete internalization was not as efficient, suggesting that receptor internalization is required but not sufficient for ubiquitinylation and degradation. We propose that the ability of FTY720-P to target the S1P 1 receptor to the ubiquitinylation and proteosomal degradation pathway may at least in part, underlie its immunosuppressive and anti-angiogenic properties.
INTRODUCTION

Sphingosine
1-phosphate (S1P) is recognized as a multifunctional bioactive lipid mediator involved in immune cell trafficking, regulation of vascular permeability, and angiogenesis (1, 2) . It acts via a family of G proteincoupled receptors referred to as S1P n receptors (3). The prototypical receptor, S1P 1 was originally isolated as an inducible gene from vascular endothelial cells (4) . Knock-out of S1P 1 resulted in embryonic lethality due to a vascular maturation defect (5) . We recently showed that S1P 1 function in endothelial cells is needed for proper endothelialpericyte interaction, a critical event in vascular maturation (6) .
In addition, we demonstrated previously that S1P 1 is needed for the assembly of VE-cadherin-based adherens junctions on vascular endothelial cells (7) . This event is needed for regulation of paracellular permeability, a model system vascular leak syndrome (8) . In the immune system, selective deletion of S1P 1 in T-cells led to inhibition of lymphocyte egress from lymph nodes and the thymus (9, 10) . However, function of S1P 1 in efferent lymphatics may also be important for the regulation of lymphocyte egress; as activation of this receptor may lead to "gate closure" at mesenteric lymphatics leading to "logjamming" of lymphocytes (11, 12) . These studies point to the crucial role played by the S1P 1 receptor in the regulation of vascular and immune physiology.
The immune modulator, FTY720, which is undergoing phase III clinical trials for multiple sclerosis and allograft rejection, is known to interact with and modulate the function of S1P 1 receptor (13) (14) (15) . The prodrug form of FTY720 is phosphorylated by sphingosine kinase-2 into FTY720-P (16, 17) , a potent nanomolar agonist on S1P 1 , S1P 3 , S1P 4 and S1P 5 (13, 14) . Acute agonism of S1P 1 with FTY720-P leads to similar cellular effects as S1P, including intracellular calcium rise, adenylate cyclase inhibition, MAP kinase activation, VE-cadherin assembly and cell migration (18) . Both S1P and FTY720-P induce receptor internalization into the endosomal pathway (19, 20) . However, in FTY720-treated cells, the S1P 1 receptor does not recycle to the plasma membrane (20, 21) . The significance of this finding is not clear, even though it was hypothesized that the ability of FTY720 to downregulate the receptor from the plasma membrane may underlie its immunosuppressive action (10, 18) .
In vivo, FTY720 exerts profound effects on immune and vascular systems. In the immune system, it induces rapid yet sustained lymphopenia, dendritic cell migration, B-cell trafficking and hematopoietic stem cell homing (18, 22) . Vascular effects of FTY720 include the inhibition of vascular permeability and angiogenesis (16, 23) . The apparent antagonistic nature of the in vivo effects of FTY720 were surprising in light of the fact that it is an agonist for the S1P 1 receptor, which is a proangiogenic and pro-migratory receptor (24) (25) (26) . A variety of explanations were proposed, including functional antagonism and vascular gate closure (3, 12) . However, systematic examination of the fate of S1P 1 when activated by agonists has not been conducted.
In this report, we show that FTY720-P is a potent activator of the ubiquitinylation of the S1P 1 receptor. This modification results in rapid and quantitative degradation of S1P 1 . We suggest that the ability of pharmacologic agonists to target S1P 1 degradation may underlie, at least in part, their immunosuppressive and anti-angiogenic properties.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents -Sphingosine and Sphingosine 1-Phosphate were purchased from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA). FTY720, FTY720-P and (R)-AFD were kindly provided Novartis Pharma, Basel, Switzerland. SEW 2871 was purchased from Maybridge. VPC 01211 and VPC 44116 were synthesized as described (27, 28) . Fatty acid-free bovine serum albumin (BSA), β-glycerophosphate, β-actin antibody, MG132 were from Sigma, ubiquitin monoclonal antibody (MMS-258R) was from Covance, ubiquitin monoclonal antibody (P4D1) was from Santa-Cruz. S1P 1 (E49) monoclonal antibody -E. coli derived human S1P 1 full length antigen (29) was used to develop a murine monoclonal antibody using established procedures (30) . Anti-S1P 1 monoclonal IgG was purified from hybridoma cell supernantants using protein A Sepharose.
Cell Culture and Transfection -HEK293 cells stably expressing S1P 1 -GFP wild type and its various mutants (19) were grown in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen), 50 units/ml penicillin and 50 µg/ml streptomycin (Invitrogen), and maintained at 37 ° C in a water-saturated atmosphere of 5% CO 2 in air. Human umbilical vein endothelial cells (HUVEC) (Clonetics, p4-9) were cultured in M199 medium supplemented with containing 10% fetal bovine serum and heparin-stabilized endothelial growth factor, as previously described (4). HEK293 cells were transfected with the indicated expression plasmids using calcium phosphate-mediated method (31) or LipofectAMINE 2000 transfection reagent or oligofectamine (Invitrogen) according to the manufacturer's instructions.
DNA and siRNA Constructs-S1P 1 -GFP (wild-type, ∆I, ∆III, S5A mutants) in the vector pCDNA3 were either generated by polymerase chain reaction (PCR) -based mutagenesis or described previously (19) . In short, the ∆I and ∆III constructs were terminated at the residue #334 and #362, respectively and fused with the GFP polypeptide. siRNAs for GRK2 [bases 267-288 from the start codon; target sequence (5' AAGAAGUACGAGAAGCUGGAG 3')], nonsilencing control sequence (5' AAGUGGACCCUGUAGAUGGCG 3') (32), β-arrestin 1, β-arrestin 2 and both (33) were prepared by Silencer siRNA construction kit (Ambion) according to manufacturer's protocol or purchased from Dharmacon Research (Lafayette, CO).
Analysis of S1P 1 Degradation by Immunoblotting-HUVEC (4 x 10 5 ) were cultured in M199 medium growth medium containing serum for 3 days. Cells were serum-starved in M199 medium without serum and other growth factors for 2 hours and then incubated in the same media with S1P, FTY720-P or their analogs for indicated times. Cells were washed with PBS and lysed by addition of SDS sample buffer, sonication, followed by heating at 95° C for 5 minutes. Protein concentrations were determined by Bio-Rad assay (Bio-Rad protein dye reagent). Equal amounts of proteins were separated on a 10% polyacrylamide gel and transblotted onto nitrocellulose membrane. Blots were incubated with an anti-S1P 1 monoclonal antibody (E49) and analyzed by chemiluminescence (Amersham). Blots were then stripped and probed using β-actin primary antibody (Sigma). Films were scanned and normalized for total protein using the β-actin blots.
HEK293 stable clones of S1P 1 wild type and its mutant variants grown to 50 -65% confluency in 6 well plates. The next day cells were incubated in 2% charcoal-stripped serum for 2 days and allowed to grow for an additional 2 hour in DMEM. Cells were then treated with indicated various ligands in time course or dose response and analysed as described above for HUVEC.
Immunofluorescence Confocal Microscopy -2 x 10 5 cells were plated in fibronectin coated 35-mm glass-bottom Petri dishes. One day later for HEK 293, cells were incubated in 2% Charcoal-treated FBS for 2 days, washed and serum-starved 3 h prior to treatment. Then cells were washed with ice-cold phosphate-buffered saline and fixed and examined using a confocal microscope. For immunofluorescence analysis, S1P 1 (E49) monoclonal antibody was applied and antibody staining was visualized with Alexa Fluor 488 donkey anti-goat for monoclonal (1:2000) IgG (Molecular Probes). Confocal microscopy was conducted on a Zeiss LSM 510 laser-scanning confocal microscope. Fluorescence was excited using a 488-nm argon laser, and emitted light was detected with 505-nm long-pass filter.
Detection of Ubiquitinated Receptors -HEK 293 cells stably expressing S1P 1 -GFP (90% confluency) cells were starved in 2% charcoal-stripped serum for 2 days. Then they were incubated for an additional 2 hrs in DMEM with the proteosomal inhibitor 20 µM MG132. Cells were incubated with receptor agonists and antagonists and lysed in (50 mM Tris pH 7.4, 1% Triton, 500 mM NaCl, 10 mM MgCl 2 , 50 mM β-glycerophosphate, 0.5 mM Na 3 VO 4 , 0.1 mM Na 2 MoO 4 , 10 mM NaF, 20 mM CHAPS). Cell lysates were immunoprecipitated with anti-S1P 1 (E49) IgG beads or ubiquitin (P4D1) IgG beads for overnight and S1P 1 or ubiquitin bound proteins were separated in 10 % SDS-PAGE gel and probed with ubiquitin antibody or E49 antibody and re-probed by E49 or ubiquitin antibody.
RESULTS AND DISCUSSION
S1P 1
receptor undergoes rapid internalization via the endosomal pathway upon agonist stimulation (19) . The fate of endocytosed S1P 1 after stimulation by various agonists is not well-characterized. Therefore, we examined whether endogenously expressed S1P 1 is endocytosed in HUVEC using the monoclonal antibody E49 to detect the S1P 1 antigen. As shown in Figure 1A , E49 detected the S1P 1 protein specifically in transfected CHO and S1P 1 -GFP fusion protein in HEK293 cells. Heterogeneity of the immunoreactive bands most-likely represent post-translationally modified receptor species, such as glycosylation and/or phosphorylation. In addition, lower M r bands could also be due to proteolysis. The immunoreactivity was competed by the E. coliderived S1P 1 antigen (29) but not by the irrelevant (Glutathione S-transferase; GST) antigen ( Figure  1B ).
Immunofluorescence analysis of HUVEC indicated that the receptor was localized on the punctate regions of the plasma membrane, in particular in cell-cell contact areas in confluent HUVEC. The epitope detected by E49 is localized on the extracellular surface since strong membrane staining was observed in non-permeabilized cells (data not shown). Treatment with S1P or FTY720-P strongly induced receptor endocytosis. However, when the ligands were washed away and cells incubated with cycloheximide to block new protein synthesis (19) , S1P 1 recycled back to the plasma membrane within 2 h in S1P-treated cells whereas it remained in the endosomal structures in the FTY720-P treated cells ( Figure 1C) . Thus endogenously expressed S1P 1 behaves similarly to the behavior of S1P 1 -GFP fusion protein in HEK293 cells (19) (20) (21) . However, in HUVEC, native S1P 1 appears in a punctate pattern compared to the HEK293 cell, in which a smooth membrane pattern is seen.
We determined the expression level of S1P 1 in HUVEC after treatment with various agonists. As shown in Figure 2 . the physiological ligand S1P only modestly reduced receptor levels whereas sphingosine did not have an effect. Interestingly, FTY720-P caused a dramatic reduction in endogenous S1P 1 expression. The precursor, FTY720 was inactive. A chiral analog of FTY720-P, (R)-AFD behaved similarly. SEW2871, a lower potency S1P 1 -specific agonist (EC 50 ~ 13.8 + 8.3 nM vs. 0.4 + 0.24 nM for S1P) did not induce suppression of receptor expression at lower concentrations (10-250 nM) (Figure 2 ). Higher concentrations of SEW2981 (1-2.5 µM) suppressed receptor expression ~ 30%, which is equivalent to the suppression achieved by 250 nM S1P (data not shown). The time-course experiment showed that FTY720-P decreased receptor levels within 0.25 -1 hr after treatment in HUVEC ( Figure 3A) . In HEK293 cells expressing S1P 1 -GFP receptor, sustained suppression (0.25 -12 h) of receptor expression was observed. These data suggest that pharmacological agonists and supraphysiological concentrations of the natural ligand S1P suppresses S1P 1 receptor expression levels in HUVEC and HEK293 cells.
That FTY720-P and (R)-AFD are the most potent ligands at down-regulation of receptor expression is surprising because such agonists have similar affinities and are capable of acutely desensitizing the S1P 1 receptor as the natural ligand, S1P (13, 14) . It is possible that the phosphate moiety of S1P is more labile to the action of plasma membrane-or endosome-associated phosphatases. However, SEW2981, which does not contain a phosphate moiety, was not effective at inducing receptor degradation, suggesting that FTY720-P and (R)-AFD may induce a unique perturbation of receptor conformation and/or oligomerization so as to down regulate the S1P 1 receptor.
We next tested the effect of VPC 44116, a potent S1P 1 antagonist (27, 28) on receptor internalization and FTY720-P induced downregulation of the S1P 1 receptor. As shown in Figure  4 , VPC 44116 alone did not have an effect on the localization of S1P 1 -GFP in HEK293 cells. However, at 100-500 nM, VPC 44116 potently inhibited the ability of S1P (100 nM) and FTY720-P (10 nM) to induce receptor internalization, as expected of a potent antagonist. Similar findings were observed with the endogenously-expressed S1P 1 receptor in HUVEC (data not shown).
In HUVEC, VPC 44116 treatment rescued FTY720-P induced S1P 1 receptor suppression in a time and dose dependent manner ( Figure 5A & B) . Similarly, VPC 44116 prevented FTY720-Pinduced S1P 1 -GFP degradation in HEK293 cells (data not shown). These findings provide evidence that receptor agonism is required but not sufficient for FT720-P-induced down-regulation. Interestingly, treatment of HUVEC with VPC 44116 enhanced basal level of receptor expression within 60 min, suggesting that autocrine signaling of S1P 1 in HUVEC induces receptor downregulation under steady-state conditions ( Figure 5C ). It is known that HUVEC produce significant quantities of S1P and is capable of secreting this lipid mediator into the extracellular environment (34) . In addition, HUVEC also express the sphingosine kinase-1a isoform, which can act as an ectokinase (34, 35) . Therefore, endogenously-produced S1P may interact with the S1P 1 receptor to signal in an autocrine manner. Such an autocrine signaling module in the vascular endothelial cells may have functional consequences, as S1P 1 is important in the inhibition of vascular permeability (7, 8) , regulation of actin-and microtubule-based cytoskeleton (6, 7, 26) , suppression of the inflammatory response (36, 37) and the regulation of the angiogenic response (25) .
Next, we determined if receptor internalization is needed for FTY720-P-induced S1P 1 degradation (19). We used stable HEK293 cells expressing various C-terminal mutants of S1P 1 receptor. Previous studies from our laboratory have shown that successive deletion of the C-terminal of S1P 1 receptor caused inhibition of ligand-induced internalization (19) . Such mutants were used in the present study to determine if FTY720-P is capable of inducing S1P 1 degradation in the absence of GPCR internalization. In addition, Watterson et al. have shown that a conserved serine-rich region (SRR) in the C-terminal tail of S1P 1 is phosphorylated by G protein-coupled receptor kinase-2 (GRK-2) and protein kinase-C (PKC) (38) . Our previous data suggest that SRR domain is essential for S1P-induced receptor internalization (19) . We therefore, prepared a mutant S1P 1 Figure 6 , the resulting mutant, S1P 1 -S5A-GFP was expressed in HEK293 cells and transported to the plasma membrane. S1P and FTY720-P induced ERK phosphorylation, Akt phosphorylation and cell migration in transfected CHO cells in an indistinguishable manner when the wild-type and the S5A mutant receptors were compared (data not shown). These results suggest that ligand binding and acute signaling of the S1P 1 -S5A-GFP mutant is not altered by the C-terminal mutation.
When HEK293 cells stably-transfected with the C-terminal mutants were treated with FTY720-P, receptor degradation was not observed in S1P 1 -∆I-GFP and S1P 1 -S5A-GFP. In contrast S1P 1 -∆III-GFP was degraded in a similar manner as the wild-type receptor. Thus, there is strict correlation between agonist-induced receptor internalization and suppression of receptor expression. Therefore, SRR phosphorylation consensus site of S1P 1 receptor is necessary not only for FTY720-P-induced receptor endocytosis but also for down-regulation of receptor expression.
To test if GRK-2, an essential kinase involved in the agonist-induced phosphorylation of GPCRs, is needed for S1P 1 degradation, we suppressed GRK-2 expression by a specific siRNA (32) . As shown in Figure 8A , degradation of S1P 1 was not detected in GRK2 siRNA treated cells.
Next, we tested the role of β-arrestins, which bind to phosphorylated motifs on activated GPCRs to induce receptor desensitization and facilitate endocytosis. As shown in Figure 8B , coadministration of siRNA for β-arrestin-1 and -2 rescued the receptor from FTY720-P induced degradation. Together, these results suggest that GRK2 mediated receptor phosphorylation and β-arrestin-dependent receptor internalization is required for FTY720-P induced S1P 1 degradation. These experiments further confirm that receptor endocytosis machinery, i.e., kinases that phosphorylate the receptor and the adaptor proteins that induce endocytosis of receptor-containing endosomes, are essential for FTY720-P-induced receptor down-regulation.
After internalization, GPCRs can take several fates; some are recycled back to the plasma membrane and some are targeted to be degraded in proteosomes and/or lysosomes (39, 40) . Both of these processes appear to require the ubiquitinylation of GPCRs (41, 42) . First, we tested the effect of MG132, an inhibitor of protein degradation in proteosomes (43) . Treatment with MG132 profoundly inhibited FTY720-P-induced receptor degradation in both S1P 1 -GFP expressing HEK293 cells and HUVEC ( Figure 9 ). These data suggested that S1P 1 is degraded in proteasomes following FTY720-P treatment of HUVEC and HEK 293 cells. However, we did not observe a defect in receptor internalization after the cells are treated with MG132 (data not shown), suggesting that proteosomal activity is not required for receptor internalization.
Ubiquitination of GPCRs is a critical posttranslational modification implicated in endosomal trafficking as well as sorting to proteosome/lysosomal degradation pathways (41, 44) . Since S1P and FTY720-P regulate different receptor fates, we tested if they regulate S1P 1 ubiquitinylation differentially. Ubiquitiylation of S1P 1 was detected in HEK293 cells expressing S1P 1 -GFP fusion protein by immunoprecipitation with the anti-S1P 1 -specific monoclonal antibody E49 followed by immunoblot analysis with the antiubiquitin antibody. As shown in Figure 10A , FTY720-P induced strong polyubiquitination of S1P 1 even though S1P was also capable of this modification, albeit to a lesser extent. The monoubiquitinylated species was also induced by FTY720-P and S1P. Importantly, polyubiquitinylation of S1P 1 -GFP was completely blocked by the receptor antagonist, VPC 44116. In contrast, the monoubiquintinylated species was not affected. Analysis of total ubiquitinylated proteins indicated that FTY720-P is capable of inducing stronger pattern of multiple ubiquitinylated species only in HEK293 cells expressing S1P 1 -GFP (Supplemental Figures 2 and 3) . A reciprocal immunoprecipitation experiment, when antiubiquitin antibody was used in the immunoprecipitation experiment, followed by an immunoblot analysis with the E49 antibody ( Figure  10B ) showed also that FTY720-P induced strong ubiquitinylation of S1P 1 -GFP. Immunoprecipitation with anti-ubiquitin followed by immunoblot with the same antibody also showed that FTY720-P induced strong polyubiquitinylation. These data suggest that increased polyubiquitinylation of S1P 1 may be critical for sorting into the proteosomal degradative pathway. Similar experiments in HUVEC to detect endogenous S1P 1 were not successful due to the low level expression of the receptor in HUVEC (data not shown). These data strongly suggest that FTY720-P-induced poly-ubiquitinylation of S1P 1 is responsible for the preferential targeting of the receptor into the proteosomal degradative pathway.
Studies in yeast and lymphocytes have shown that FTY720 treatment modifies the cellular ubiquitin pathway (45, 46) . In a S. cerevesiae screen, Movva and co-workers noted that enhanced ubiquitination is involved in the growth inhibition mediated by FTY720. In lymphocytes treated with FTY720, proteins involved in the ubiquitin system were modulated. Thus, FTY720-P in our system may modulate the conformation and/or oligomerization of the S1P 1 receptor in a manner such that it is preferentially targeted for the degradative pathway. It is of interest to note that only very high concentrations of S1P (> 250 nM) induced significant receptor degradation. Although plasma S1P levels are high, free or bioactive S1P in plasma is in the low nM range due to the sequestration of plasma chaperones, such as HDL and albumin (47) (48) (49) . Indeed, in situations where high local production of S1P is observed, significant receptor degradation may occur upon autocrine and/or paracrine signaling. Thus, we speculate that under physiological conditions, S1P 1 receptor may follow the recycling pathway primarily. However, under conditions where high S1P levels are present, for example, during platelet activation, immune cell activation, etc., the receptor signaling may be attenuated by the targeting of the S1P 1 receptor to the degradative pathway.
In summary, the present study establishes a novel link between ubiquitination and degradation of S1P 1 induced by FTY720-P. We show that GPCR internalization is required for degradation of S1P 1 . However, receptor internalization is not sufficient for receptor degradation, as S1P treatment which efficiently internalizes S1P 1 is not efficiently degraded. Exaggerated ubiquitinylation induced by FTY720-P targets the receptor to the proteosomal degradative pathway.
Since FTY720-P is immunosuppressive and anti-angiogenic, we speculate that ubiquitinylation and degradation of S1P 1 may at least in part be responsible for the pharmacological action of FTY720-P.
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We thank Novartis Pharma for the kind gift of FTY720 and related compounds. This work is supported by NIH grants (PO1-HL70694 and R37-HL67330 to TH); (RO1-GM67958 to KRL) and (R01-CA096851and R01-CA104944 to CYL). transiently transfected with S1P 1 or S1P 1 -GFP constructs and cell lysates were analyzed by SDS-PAGE and immunoblotted with the anti-S1P 1 (E49) monoclonal antibody as described. (B) HEK293 cells transfected with either vector or S1P 1 -GFP plasmid were analyzed by an immunoblot assay as described with the indicated antibodies (E49 anti-S1P 1 or anti-GFP oranto-β-actin. Some filters were incubated with the E. coli-derived competitor antigen and the E49 antibody as indicated. S1P 1 antigen and GST were used at 10 µg/ml. (C) HUVEC were analyzed by confocal immunofluorescence microscopy as described. Some cells were treated with vehicle, 100 nM S1P or 10 nM FTY720-P for 30 min and imaged. Other cells were washed after the treatments, and incubated with S1P-free medium for 2 h in the presence of 15 µg/ml cycloheximide and imaged as described. Note that S1P 1 receptor recycles in S1P-treated cells but not in FTY720-P-treated cells. . Effect of the S1P 1 receptor antagonist VPC 44116 on S1P and FTY720-P-induced receptor internalization. HEK293 cells stably expressing S1P 1 -GFP were preincubated for 30 min with indicated concentrations of VPC 44116. The cells were then treated for 30 min with 100 nM S1P or 10 nM FTY720-P, fixed and imaged by confocal microscopy as described. antagonist and FTY720-P for 30 min. (C) HUVEC were treated with VPC 44116 100 nM for indicated time points. S1P 1 receptor levels were determined by immunoblot analysis with the E49 antibody as described. Figure 6 . Inability of the S1P 1 -S5A-GFP receptor to undergo agonits-induced internalization. HEK293 cells stably-transfected with wild-type S1P 1 -GFP or S1P 1 -S5A-GFP constructs were treated with either vehicle, S1P (100 nM) or FTY720-P (10 nM) for 30 min, fixed and imaged with a confocal fluorescence microscopy as described. Figure 7 . SRR Phosphorylation consensus site of S1P 1 is required for FTY720-P induced S1P 1 degradation. (A) schematic representation of S1P 1 -GFP mutants and the wild-type receptor. The internalization data are from (19) and above ( Figure 6 ). (B) S1P 1 -∆III-GFP is sensitive to FTY720-P induced S1P 1 degradation whereas S1P 1 -∆I-GFP and S1P 1 -S5A-GFP are resistant. HEK293 cells stably-transfected with S1P 1 -∆III-GFP, S1P 1 -S5A-GFP and S1P 1 -∆I-GFP cells were incubated with FTY720-P (10 nM) for indicated times. All membranes were immunoblotted with E49 antibody and re-probed with the β-actin antibody. (B) Quantification of S1P 1 degradation by densitometric scanning of immunoblots. Results shown represent the mean S.E. of three independent experiments. Figure 8 . Requirement for GRK2 and β-arrestins in FTY720-P induced S1P 1 degradation. (A) GRK2 siRNA can rescue FTY720-P induced S1P 1 degradation. Control siRNA and GRK2 siRNA were transfected into HEK293-S1P 1 -GFP stable cells, incubated in 2% charcoal-treated serum for 2 days and FTY720-P 10 nM was applied in DMEM. Immunoblot analysis was conducted with S1P 1 (E49), β-actin and GRK-2 antibodies. (B) β-arrestin dependent internalization is required for S1P 1 degradation by FTY720-P. HEK293-S1P 1 -GFP stable cells were transfected with control siRNA, β-arrestin 1, β-arrestin 2, β-arrestin-1 and -2 siRNA and incubated with FTY720-P 10 nM for 30 min and 1 h. Cell lysates were separated on SDS-PAGE and immunoblotted with S1P 1 (E49), β-actin, and β-arrestin-1 and -2 antibodies. Figure 9 . The proteasomal inhibitor, MG132 rescues FTY720-P induced S1P 1 degradation in HEK293-S1P 1 -GFP stable cells and in HUVEC. Indicated cells were incubated with or without MG132 (20 µM) for 2 h before FTY720-P 10 nM for indicated times. S1P 1 levels were determined by immunoblot analysis as described. were incubated with S1P (100 nM) or FTY720-P (10 nM) for 15 min in the presence or absence of VPC 44116 (500 nM). Solubilized S1P 1 receptor was immunoprecipitated by E49 monoclonal IgG beads and immunoblotted with the ubiquitin IgG. In the lower panel, immunoprecipitates were reacted with the GFP antibody which primarily detected the non-entensively modified S1P 1 -GFP polypeptide. (B) Solubilized S1P 1 receptor was immunoprecipitated with the ubiquitin monoclonal IgG (P4D1, Santa Cruz) beads and its immunoblotted with the E49 IgG (left panel). The membrane was re-probed with the same IgG (middle panel). Input cell lysates were detected by direct immunoblot with S1P 1 (E49) (right panel-top) and β-actin antibody (right panel-bottom).
Supplemental Figure 1 . Specificity of the E49 antibody. HEK293 cells expressing S1P 1 -GFP were solubilized and cell extracts were immunoprecipitated with either an irrelevant cyclin B1 monoclonal antibody or the E49 antibody. Immunoprecipitates were immunoblotted with the E49 antibody as described. Note the specific detection of the S1P 1 -GFP polypeptide by the E49 antibody. Bands around 64 Kd M r marker likely represent heavy chain of the IgG.
Supplemental Figure 2 . Analysis of protein ubiquitinylation in HEK293 cells expressing S1P 1 -GFP. HEK293 cells expressing S1P 1 -GFP were treate with MG132 for 2 h and stimulated with S1P or FTY720-P for indicated times. Cell extracts were analyzed by immunoblot analysis with anti-Ub antibody as described. Note that FTY720-P induced stronger ubiquitinylation patterns in a time-dependent manner.
Supplemental Figure 3 . Analysis of protein ubiquitinylation in HEK293 cells expressing GFP. Similar analysis as supplemental figure 2 was done on HEK293 cells expressing the control GFP polypeptide. FTY720-P and S1P-treated cells exhibited similar patterns of protein ubiquitinylation.
